Ajanta Pharma has earmarked a capex plan of Rs 250 crore for FY22. The company is likely to use the same towards maintenance and some new expansions for the corporate office and some key expansions in the facility. The company operates eight manufacturing facilities in India and Mauritius, including two plants which have been approved by the US Food and Drug Administration (USFDA).
Earlier, the company had earmarked a capex plan of Rs 150 crore for the 2019-20 fiscal. The company had invested Rs 30 crore in the expansion of the corporate office last year, and this year it is going to be in the range of Rs 60-80 crore.
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: